Novare Capital Management’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $12.4M | Buy |
57,096
+255
| +0.4% | +$56.6K | 0.98% | 33 |
|
|
2025
Q4 | $13M | Sell |
56,841
-838
| -1% | -$191K | 0.97% | 34 |
|
|
2025
Q3 | $13.4M | Sell |
57,679
-621
| -1% | -$126K | 1.02% | 30 |
|
|
2025
Q2 | $10.8M | Buy |
58,300
+1,362
| +2% | +$253K | 0.88% | 40 |
|
|
2025
Q1 | $11.9M | Sell |
56,938
-1,254
| -2% | -$244K | 1.04% | 36 |
|
|
2024
Q4 | $10.3M | Buy |
58,192
+5,341
| +10% | +$982K | 0.87% | 43 |
|
|
2024
Q3 | $10.4M | Buy |
52,851
+6,072
| +13% | +$1.13M | 0.88% | 44 |
|
|
2024
Q2 | $8.02M | Buy |
46,779
+41,920
| +863% | +$6.94M | 0.72% | 54 |
|
|
2024
Q1 | $885K | Sell |
4,859
-1,643
| -25% | -$283K | 0.08% | 111 |
|
|
2023
Q4 | $1.01M | Sell |
6,502
-266
| -4% | -$38.8K | 0.1% | 108 |
|
|
2023
Q3 | $1.01M | Sell |
6,768
-60
| -0.9% | -$8.81K | 0.11% | 103 |
|
|
2023
Q2 | $920K | Sell |
6,828
-170
| -2% | -$24.9K | 0.1% | 109 |
|
|
2023
Q1 | $1.12M | Sell |
6,998
-245
| -3% | -$37.5K | 0.13% | 101 |
|
|
2022
Q4 | $1.17M | Sell |
7,243
-1,760
| -20% | -$270K | 0.14% | 100 |
|
|
2022
Q3 | $1.21M | Sell |
9,003
-371
| -4% | -$53.2K | 0.15% | 92 |
|
|
2022
Q2 | $1.44M | Sell |
9,374
-2,174
| -19% | -$332K | 0.18% | 88 |
|
|
2022
Q1 | $1.87M | Sell |
11,548
-2,809
| -20% | -$408K | 0.2% | 83 |
|
|
2021
Q4 | $1.94M | Sell |
14,357
-3,130
| -18% | -$370K | 0.2% | 84 |
|
|
2021
Q3 | $1.89M | Sell |
17,487
-423
| -2% | -$48.3K | 0.21% | 86 |
|
|
2021
Q2 | $2.02M | Sell |
17,910
-58,097
| -76% | -$6.54M | 0.23% | 83 |
|
|
2021
Q1 | $8.22M | Buy |
76,007
+1,620
| +2% | +$173K | 0.99% | 43 |
|
|
2020
Q4 | $7.97M | Buy |
74,387
+1,553
| +2% | +$149K | 1.04% | 34 |
|
|
2020
Q3 | $6.38M | Buy |
72,834
+1,658
| +2% | +$156K | 0.9% | 46 |
|
|
2020
Q2 | $6.99M | Buy |
71,176
+3,123
| +5% | +$275K | 1.05% | 32 |
|
|
2020
Q1 | $5.18M | Buy |
68,053
+4,855
| +8% | +$414K | 0.91% | 44 |
|
|
2019
Q4 | $5.6M | Buy |
63,198
+131
| +0.2% | +$10.9K | 0.78% | 62 |
|
|
2019
Q3 | $4.78M | Buy |
63,067
+6,565
| +12% | +$450K | 0.71% | 67 |
|
|
2019
Q2 | $4.11M | Sell |
56,502
-638
| -1% | -$50.1K | 0.63% | 68 |
|
|
2019
Q1 | $4.61M | Buy |
57,140
+7,440
| +15% | +$609K | 0.72% | 64 |
|
|
2018
Q4 | $4.58M | Buy |
49,700
+2,684
| +6% | +$236K | 0.84% | 53 |
|
|
2018
Q3 | $4.36M | Buy |
47,016
+170
| +0.4% | +$16.1K | 0.7% | 57 |
|
|
2018
Q2 | $4.34M | Sell |
46,846
-2,294
| -5% | -$224K | 0.74% | 59 |
|
|
2018
Q1 | $4.65M | Sell |
49,140
-4,990
| -9% | -$548K | 0.81% | 55 |
|
|
2017
Q4 | $5.24M | Sell |
54,130
-795
| -1% | -$74.9K | 0.89% | 47 |
|
|
2017
Q3 | $4.88M | Buy |
+54,925
| New | +$4.18M | 0.86% | 48 |
|
Other funds holding ABBV
VCM
VPM
Novare Capital Management's ABBV Position: Q1 2026 in Review
Novare Capital Management increased its AbbVie (ABBV) stake by 0.45% in Q1 2026, buying an estimated $56.6K and bringing the position to 57,096 shares worth $12.4M. The position accounts for 0.98% of the portfolio, ranked #33.
Novare Capital Management first reported a position in ABBV in Q3 2017 and has held it in 35 quarters since. The position peaked at $13.4M in Q3 2025. 4,078 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.
- Novare Capital Management held 57,096 shares of AbbVie worth $12.4M as of Q1 2026.
- Novare Capital Management bought 255 AbbVie shares in Q1 2026, an estimated $56.6K.
- AbbVie made up 0.98% of Novare Capital Management's portfolio in Q1 2026, its #33 holding.
- Novare Capital Management first reported a position in AbbVie in Q3 2017 and has held it in 35 quarters since.
- Novare Capital Management's AbbVie position peaked at $13.4M in Q3 2025.
- 4,078 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.
Based on Novare Capital Management's 13F filing for Q1 2026, filed 17 Apr 2026.